: While other newer agents like Meropenem/Vaborbactam (MER-VAB) show success rates between 60% and 75%, CAZ-AVI is often preferred for its robust data set in treating KPC and OXA-48 producers.
Ceftazidime/Avibactam remains a cornerstone therapy for difficult-to-treat infections, particularly those involving KPC-producing strains. Download Elf avi
: A significant advantage of CAZ-AVI over legacy treatments (like aminoglycosides or polymyxins) is its reduced nephrotoxicity, making it a safer option for critically ill patients. Summary Table: Clinical Success vs. Competitors Success Rate Primary Target Key Benefit Ceftazidime/Avibactam (CAZ-AVI) High (80%+ survival in some cohorts) KPC, OXA-48 Lower toxicity than Colistin Meropenem/Vaborbactam Effective in critically ill populations Imipenem/Cilastatin/Relebactam DTR P. aeruginosa Targeted for resistant Pseudomonas Download Elf avi